Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens. Issue 4 (3rd September 2019)

• Record Type: Journal Article
• Authors: Ferretti, Francesca; Mackie, Nicola E.; Singh, Gurmit Kaur Jagjit; Fox, Julie; Kaye, Steve; McClure, Myra O.; Taylor, Graham; Boffito, Marta
• Is Part Of: HIV research & clinical practice. Volume 20:Issue 4/5(2019)
• Page Start: 107
• Page End: 110
• Publication Date: 2019-09-03
• Subjects: HIV -- Resistance -- Low level viremia -- Gag -- Protease inhibitors; HIV Infections -- therapy; Acquired Immunodeficiency Syndrome -- therapy; Clinical Trials as Topic; Clinical Medicine; AIDS (Disease) -- Treatment -- Periodicals; AIDS (Disease) -- Treatment; Periodicals; Periodical; 616.9792
• DOI: 10.1080/25787489.2020.1716159
• Languages: English
• ISSNs: 2578-7489

Abstract

Abstract : To understand the pathogenesis of low level viraemia (LLV) in HIV-infected patients on boosted protease inhibitors (PI/b), we enrolled 34 subjects with a median HIV-RNA 79 copies/mL and followed them for 15 months. Samples for next generation sequencing were collected at three time-points. Two showed resistance-associated mutations (RAMs) in the protease gene, while 95–100% had RAMs in the gag gene, which evolved in approximately a quarter of subjects, suggesting a potential clinical role of these kind of mutations.